Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

The extent of cross-protection is a key element in the choice of human papillomavirus (HPV) vaccine to use in vaccination programmes. We compared the cross-protective efficacy of the bivalent vaccine (HPV 16 and 18; Cervarix, GlaxoSmithKline Biologicals, Rixensart, Belgium) and quadrivalent vaccine (HPV 6, 11, 16, and 18; Gardasil, Merck, Whitehouse Station, NJ, USA) against non-vaccine type HPVs.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Lancet Infect Dis

Title: The Lancet. Infectious diseases

Publisher: Elsevier BV

ISSN (Electronic): 1474-4457

ISSN (Print): 1473-3099

Publication date (Electronic): Oct 2012

Volume: 12

Issue: 10

Affiliations

[1 ] Unité de Recherche en Santé des Populations (URESP), Centre de Recherche Fonds de la Recherche en Santé du Québec (FRSQ) du Centre Hospitalier Affilié Universitaire de Québec (CHA), Quebec, Canada.

Article

Publisher Item ID: S1473-3099(12)70187-1

DOI: 10.1016/S1473-3099(12)70187-1

PubMed ID: 22920953

SO-VID: d49a5229-5707-443a-a407-d4d4a260fcb2

History

Data availability:

Comments

Comment on this article

scite_

Cited by 132

See all cited by

- Version 1
- Version 1